[Visceral leishmaniasis associated with human immunodeficiency virus infection (reply)].
Berenguer
Juan
J
Cosín
Jaime
J
Miralles
Pilar
P
López
Juan Carlos
JC
Padilla
Belén
B
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control*; D000666:Amphotericin B / Q000008:administration & dosage* / Q000627:therapeutic use; D000965:Antimony / Q000008:administration & dosage* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control*; D011446:Prospective Studies; D012008:Recurrence; D013030:Spain / Q000453:epidemiology; D019562:Viral Load
D000666:Amphotericin B; D000965:Antimony